Introduction {#s1}
============

Rheumatoid arthritis (RA) is known as a common autoimmune, inflammation disease characterized by systemic manifestations of immune and inflammatory response including marginal bone erosion, inflammatory joint fluid, synovitis, and destruction of articular cartilage ([@B1], [@B2]). Several researches have indicated that the incidences of RA in different ethnic groups, geographical areas are different, and the RA prevalence is approximately 1% around the world ([@B3], [@B4]). It has been revealed that genetic susceptibilities, abnormal metabolic enzymes, aberrant immune response are involved in RA development ([@B5], [@B6]). Latterly, a number of single nucleotide polymorphisms (SNPs), the majority of which are located in the non-coding intervals, are gradually identified to be associated with the susceptibility of this disease according to genome-wide association studies ([@B7], [@B8]).

Long non-coding RNAs (lncRNAs), which are defined as RNAs longer than 200 nucleotides in length, have no or little protein-coding capacity ([@B9]). LncRNAs are reported to be involved in a variety of autoimmunity- and inflammation- related processes, and regulate gene expression in multiple mechanisms including alternative splicing, epigenetics, small RNA sponging ([@B10], [@B11]). Increasing studies have been performed to explore the potential role of lncRNAs on the pathogenesis of autoimmune diseases, such as RA and systemic lupus erythematosus (SLE) ([@B12]--[@B14]). Our recent study demonstrated that the lnc0640, lnc5150 expression levels were alternated among RA patients, and *lnc0640* rs13039216 TT genotype was statistically associated with RA susceptibility ([@B14]). Another previous study suggested that aberrant lncRNA expression level in peripheral blood mononuclear cells (PBMCs) could be a potential biomarker for RA diagnosing ([@B13]).

Recently, lncRNA ANRIL (antisense non-coding RNA in the INK4 locus) had attracted attention in autoimmune diseases, as it had been implicated in regulation of immune, inflammatory response ([@B15]). ANRIL expression was found to be regulated through STAT1 signaling pathway, which participated in immune regulation by induction of the pro-inflammatory cytokine TNF-γ ([@B16]). In addition, another study indicated that ANRIL expression level in PBMCs was decreased in RA by lncRNA array ([@B13]). Dendritic cell (DC) was a specific antigen presenting cell which link the innate and adaptive immune responses, and was thought to drive the activation of self-peptide-reactive inflammatory T cells, follicular helper T cells and consequently B cells for secreting autoantibodies in RA ([@B17]). Lnc-DC was a specialized, highly expressed lncRNA in DCs, and had the ability to regulate Th17 differentiation, DCs to stimulate T cell activation, and the production of interleukin 12 (IL-12) ([@B9]). LncRNA MALAT1 (metastasis-associated lung adenocarcinoma transcript-1) had been shown to play a role in the development of autoimmune diseases. SLE patients had increased MALAT1 level in PBMCs compared with normal individuals, and knockdown of MALAT-1 significantly suppressed IL-21 level in monocytes ([@B18]). In RA, Pan et al. found that knockdown of MALAT1 could inhibit the apoptosis of fibroblast-like synoviocytes (FLS) and lead to the activation of phosphoinositide 3-kinase (PI3K)/AKT signaling pathway ([@B19]). In another study, lncRNA ZFAS1 (zinc finger antisense 1) was shown to participate in RA-FLS migration and invasion by interacting with miR-27a and suppressing miR-27a expression, and ZFAS1 expression level was statistically evaluated in FLS of RA patients ([@B20]).

These studies demonstrated that ANRIL, lnc-DC, MALAT1, ZFAS1 might be involved in the occurrence and development of RA. However, no studies regarding the relationship between these lncRNAs genetic variation and RA have been reported. Thus, in the present study, we explored the associations of these lncRNAs genes SNPs with RA risk, as well as these lncRNAs expressions in PBMCs of RA patients and normal controls.

Materials and Methods {#s2}
=====================

Patients and Normal Controls
----------------------------

In this study, case-control studies were performed in unrelated ethnic Han Chinese population. A total of 1,370 subjects including 660 RA patients and 710 normal controls were consecutively enrolled to investigate the association between *ANRIL, lnc-DC, MALAT1, ZFAS1* genes polymorphisms and RA susceptibility. Then, 120 RA patients and 120 normal controls were included to detect these lncRNAs expression levels. RA patients were selected from the First Affiliated Hospital of University of Science and Technology of China, and the First Affiliated Hospital of Anhui Medical University. The diagnosis of these patients was according to the 1987 American College of Rheumatology revised criteria ([@B21]). The normal controls, who were recruited from the healthy blood donors in the same region, did not have no a history of RA, or other inflammatory/autoimmune diseases, cancer. Disease Activity Score 28 (DAS 28) was used to evaluate RA disease activity ([@B22]). The demographic data of all subjects were collected, and the following clinical data of RA patients were retrieved from the medical records: complements 3 (C3), complements 4 (C4), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), anti-cyclic citrullinated peptide (anti-CCP), and rheumatoid factor (RF). After informed consent was obtained, peripheral blood samples and data were collected from RA patients and normal controls. This study protocol was approved by the Medical Ethics Committee of Anhui Medical University.

SNP Selection, DNA Extraction, and Genotyping
---------------------------------------------

The genetic and location information were obtained from two public databases, LNCipedia.org (v4.0) and Genome Browser Gateway (UCSC). We selected the tagSNPs with a minor allele frequency (MAF) ≥ 0.05 in CHB capturing all the common SNPs located in the chromosome locus transcribed into these lncRNAs (*ANRIL, lnc-DC, MALAT1, ZFAS1*) and their flanking 2,000 bp region through using genotype data of Han Chinese in Beijing from Ensembl genome browser 85 and CHBS_1000 g. The selection was conducted through linkage disequilibrium (LD) analysis with *r*^2^ threshold \> 0.8 by using Haploview 4.0 software (Cambridge, MA, USA). In addition, the existing studies about these lncRNA genes polymorphisms were also reviewed. Finally, we selected six tagSNPs (rs1412830, rs7044859, rs944796, rs61271866, rs2518723, rs3217992) in *ANRIL, two* tagSNPs (rs7217280, rs10515177) in *lnc-DC*, five tagSNPs (rs619586, rs4102217, rs591291, rs11227209, rs35138901) in *MALAT1*, four tagSNPs (rs237742, rs73116127, rs6125607, rs6125608) in *ZFAS1* for genotyping in the present study.

The genomic DNA was extracted from the peripheral blood leukocytes by the Flexi Gene-DNA Kit (Qiagen, Valencia, CA). Improved multiple ligase detection reaction (iMLDR) genotyping assay, with technical support from the Center for Genetic & Genomic Analysis, Genesky Biotechnologies (Inc., Shanghai), was used for genotyping. Those individuals with 100% genotyping success rate for the above SNPs were included for final analysis.

Quantitative Real-Time Reverse Transcription Polymerase Chain Reaction (qRT-PCR)
--------------------------------------------------------------------------------

PBMCs were isolated from 5 ml anticoagulated peripheral blood, and stored at −80°C until processed. Total RNA in PBMCs was extracted with TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) and the concentration of RNA was quantified using NanoDrop 2000 spectrophotometer (Thermo Scientific, USA). Then, the PrimeScriptTM RT reagent Kit (Takara Bio Inc., Japan) was used to reverse-transcribed total RNA into cDNA.

The expression levels of ANRIL, lnc-DC, MALAT1, ZFAS1 in PBMCs were detected by qRT-PCR with SYBR Green (SYBR Premix Ex Taq II, Takara Bio Inc., Japan). This experiment was performed on QuantStudio 12K Flex Real-Time PCR System (Applied Biosystems, Foster City, CA, USA), and according to the following cycle conditions: 95°C for 1 min, followed by 42 cycles at 95°C for 10 s, 60°C for 30 s and 72°C for 1 min. The relative expression levels of lncRNAs were calculated by comparison with housekeeping gene β-actin in the same sample as internal control, and expressed using 2^−ΔΔCt^ method normalized to endogenous control ([@B23]).

Statistical Analysis
--------------------

Statistical analysis was performed with the SPSS 23.0 (SPSS Inc., IL, USA). We performed Hardy-Weinberg equilibrium test by Chi-square (χ^2^) among normal controls. For the associations of genotype, allele distribution frequencies of each SNP with RA were estimated by logistic regression analyses. The lncRNAs levels were shown as median value and interquartile range, and the differences in lncRNAs levels between two groups, three groups were analyzed by Mann-Whitney *U*-test, Kruskal-Wallis *H*-test, respectively. The correlations between lncRNAs levels and several experimental indexes of RA patients were analyzed by Spearman rank correlation coefficient test. Dominant model, recessive mode was used for statistical analysis, and haplotype analysis was conducted with the SHEsis software ([@B24]). *P* value (two-sided) \<0.05 was considered as statistically significant. False discovery rate (FRD) was used for multiple testing in SNP analysis.

Results {#s3}
=======

Association of lncRNAs Genes Polymorphisms With RA Susceptibility
-----------------------------------------------------------------

We included 546 females and 114 males in RA patients for genotyping with a median age of 51, while there were 574 females and 136 males with a median age of 49 in normal controls. The observed genotype frequencies of rs7044859 was not conform to Hardy-Weinberg equilibrium, thus we excluded this SNP in finally analysis. The results of allele and genotype frequencies of all SNPs were summarized in [Table 1](#T1){ref-type="table"}.

###### 

Genotypes and alleles frequencies of lncRNAs genes polymorphisms in RA patients and normal controls.

  **SNP**        **Analyze model**   **RA (*N* = 660) *n* (%)**   **Control (*N* = 710) *n* (%)**   **Adjustment with sex and age**               
  -------------- ------------------- ---------------------------- --------------------------------- --------------------------------- ----------- -----------------------
  ***ANRIL***                                                                                                                                     
  rs1412830      Genotypes           TT                           13 (1.97)                         3 (0.42)                          0.017       0.214 (0.060--0.761)
                                     CT                           119 (18.03)                       139 (19.58)                       0.564       1.084 (0.824--1.425)
                                     CC                           528 (80.00)                       568 (80.00)                       Reference   
                 Alleles             T                            145 (10.98)                       145 (10.21)                       0.511       0.922 (0.722--1.176)
                                     C                            1,175 (89.02)                     1,275 (89.79)                     Reference   
                 Dominant model      CC                           528 (80.00)                       568 (80.00)                       0.994       1.001 (0.766--1.307)
                                     TT+CT                        132 (20.00)                       142 (20.00)                       Reference   
                 Recessive model     TT                           13 (1.97)                         3 (0.42)                          0.016       0.211 (0.059--0.750)
                                     CC+CT                        647 (98.03)                       707 (99.58)                       Reference   
  rs944796       Genotypes           GG                           11 (1.67)                         31 (4.37)                         0.013       2.452 (1.211--4.962)
                                     GC                           238 (36.06)                       230 (32.39)                       0.236       0.872 (0.695--1.094)
                                     CC                           411 (62.27)                       449 (63.24)                       Reference   
                 Alleles             G                            260 (19.70)                       292 (20.56)                       0.572       1.055 (0.875--1.272)
                                     C                            1,060 (80.30)                     1,128 (79.44)                     Reference   
                 Dominant model      CC                           411 (62.27)                       449 (63.24)                       0.598       1.061 (0.851--1.324)
                                     GG+GC                        249 (37.73)                       261 (36.76)                       Reference   
                 Recessive model     GG                           11 (1.67)                         31 (4.37)                         0.008       2.574 (1.278--5.185)
                                     CC+GC                        649 (98.33)                       679 (95.63)                       Reference   
  rs61271866     Genotypes           AA                           25 (3.79)                         26 (3.66)                         0.882       0.958 (0.542--1.692)
                                     TA                           185 (28.03)                       214 (30.14)                       0.437       1.099 (0.867--1.392)
                                     TT                           450 (68.18)                       470 (66.20)                       Reference   
                 Alleles             A                            235 (17.80)                       266 (18.73)                       0.529       0.940 (0.774--1.141)
                                     T                            1,085 (82.20)                     1,154 (81.27)                     Reference   
                 Dominant model      TT                           450 (68.18)                       470 (66.20)                       0.498       0.924 (0.736--1.160)
                                     AA+TA                        210 (31.82)                       240 (33.80)                       Reference   
                 Recessive model     AA                           25 (3.79)                         26 (3.66)                         0.811       0.933 (0.531--1.641)
                                     TT+TA                        635 (96.21)                       684 (96.34)                       Reference   
  rs2518723      Genotypes           TT                           111 (16.82)                       133 (18.73)                       0.312       1.177 (0.858--1.613)
                                     CT                           326 (49.39)                       353 (49.72)                       0.535       1.079 (0.848--1.372)
                                     CC                           223 (33.79)                       224 (31.55)                       Reference   
                 Alleles             T                            548 (41.52)                       619 (43.59)                       0.256       1.092 (0.983--1.271)
                                     C                            772 (58.48)                       801 (56.41)                       Reference   
                 Dominant model      CC                           223 (33.79)                       224 (31.55)                       0.393       0.906 (0.721--1.137)
                                     TT+CT                        437 (66.21)                       486 (68.45)                       Reference   
                 Recessive model     TT                           111 (16.82)                       133 (18.73)                       0.413       0.890 (0.673--1.177)
                                     CC+CT                        549 (83.18)                       577 (81.27)                       Reference   
  rs3217992      Genotypes           TT                           160 (24.24)                       152 (21.41)                       0.118       0.783 (0.576--1.064)
                                     CT                           338 (51.21)                       362 (50.99)                       0.368       0.889 (0.687--1.149)
                                     CC                           162 (24.55)                       196 (27.61)                       Reference   
                 Alleles             T                            658 (49.85)                       666 (46.90)                       0.123       0.889 (0.765--1.032)
                                     C                            662 (50.15)                       754 (53.10)                       Reference   
                 Dominant model      CC                           162 (24.55)                       196 (27.61)                       0.206       1.170 (0.917--1.493)
                                     TT+CT                        498 (75.45)                       514 (72.39)                       Reference   
                 Recessive model     TT                           160 (24.24)                       152 (21.41)                       0.199       0.846 (0.656--1.092)
                                     CC+CT                        500 (75.76)                       558 (78.59)                       Reference   
  ***Lnc-DC***                                                                                                                                    
  rs7217280      Genotypes           AA                           3 (0.45)                          4 (0.56)                          0.849       1.160 (0.253--5.314)
                                     GA                           52 (7.88)                         77 (10.85)                        0.084       1.388 (0.957--2.014)
                                     GG                           605 (91.67)                       629 (88.59)                       Reference   
                 Alleles             A                            58 (4.39)                         85 (5.99)                         0.062       1.385 (0.984--1.951)
                                     G                            1,262 (95.61)                     1,335 (94.01)                     Reference   
                 Dominant model      GG                           605 (91.67)                       629 (88.59)                       0.085       0.727 (0.506--1.045)
                                     AA+GA                        55 (8.33)                         81 (11.41)                        Reference   
                 Recessive model     AA                           3 (0.45)                          4 (0.56)                          0.881       1.123 (0.245--5.146)
                                     GG+GA                        657 (99.55)                       706 (99.44)                       Reference   
  rs10515177     Genotypes           GG                           4 (0.61)                          5 (0.70)                          0.870       1.118 (0.294--4.249)
                                     GA                           94 (14.24)                        117 (16.48)                       0.330       1.159 (0.861--1.560)
                                     AA                           562 (85.15)                       588 (82.82)                       Reference   
                 Alleles             G                            102 (7.73)                        127 (8.94)                        0.251       1.173 (0.893--1.540)
                                     A                            1,218 (92.27)                     1,293 (91.06)                     Reference   
                 Dominant model      AA                           562 (85.15)                       588 (82.82)                       0.327       0.864 (0.645--1.157)
                                     GG+GA                        98 (14.85)                        122 (17.18)                       Reference   
                 Recessive model     GG                           4 (0.61)                          5 (0.70)                          0.896       1.093 (0.288--4.151)
                                     AA+GA                        656 (99.39)                       705 (99.30)                       Reference   
  ***MALAT1***                                                                                                                                    
  rs619586       Genotypes           GG                           6 (0.91)                          4 (0.56)                          0.350       0.544 (0.151--1.951)
                                     GA                           111 (16.82)                       113 (15.92)                       0.628       0.931 (0.698--1.243)
                                     AA                           543 (82.27)                       593 (83.52)                       Reference   
                 Alleles             G                            123 (9.32)                        121 (8.52)                        0.464       0.906 (0.697--1.179)
                                     A                            1,197 (90.68)                     1,299 (91.48)                     Reference   
                 Dominant model      AA                           543 (82.27)                       593 (83.25)                       0.517       1.098 (0.827--1.458)
                                     GG+GA                        117 (17.73)                       117 (16.48)                       Reference   
                 Recessive model     GG                           6 (0.91)                          4 (0.56)                          0.359       0.550 (0.153--1.973)
                                     AA+GA                        654 (99.09)                       706 (99.44)                       Reference   
  rs4102217      Genotypes           CC                           20 (3.03)                         13 (1.83)                         0.306       0.688 (0.337--1.408)
                                     CG                           154 (23.33)                       205 (28.87)                       0.020       1.340 (1.047--1.713)
                                     GG                           486 (73.64)                       492 (69.30)                       Reference   
                 Alleles             C                            194 (14.70)                       231 (16.27)                       0.257       1.128 (0.916--1.388)
                                     G                            1,126 (85.30)                     1,189 (83.73)                     Reference   
                 Dominant model      GG                           486 (73.64)                       492 (69.30)                       0.053       0.791 (0.624--1.003)
                                     CC+CG                        174 (26.36)                       218 (30.70)                       Reference   
                 Recessive model     CC                           20 (3.03)                         13 (1.83)                         0.216       0.638 (0.313--1.300)
                                     GG+CG                        640 (96.97)                       697 (98.17)                       Reference   
  rs591291       Genotypes           TT                           124 (18.79)                       132 (18.59)                       0.496       1.113 (0.818--1.513)
                                     CT                           298 (45.15)                       347 (48.87)                       0.125       1.207 (0.949--1.534)
                                     CC                           238 (36.06)                       231 (32.53)                       Reference   
                 Alleles             T                            546 (41.36)                       611 (43.03)                       0.378       1.071 (0.920--1.246)
                                     C                            774 (58.64)                       809 (56.97)                       Reference   
                 Dominant model      CC                           238 (36.06)                       231 (32.53)                       0.153       0.848 (0.677--1.063)
                                     CT+TT                        422 (63.94)                       479 (67.46)                       Reference   
                 Recessive model     TT                           124 (18.79)                       132 (18.59)                       0.979       0.996 (0.757--1.310)
                                     CT+CC                        536 (81.21)                       578 (81.41)                       Reference   
  rs11227209     Genotypes           GG                           3 (0.45)                          3 (0.42)                          0.880       0.883 (0.176--4.420)
                                     CG                           71 (10.76)                        79 (11.13)                        0.773       1.052 (0.747--1.480)
                                     CC                           586 (88.79)                       628 (88.45)                       Reference   
                 Alleles             G                            77 (5.83)                         85 (5.99)                         0.866       1.028 (0.748--1.412)
                                     C                            1,243 (94.17)                     1,335 (94.01)                     Reference   
                 Dominant model      CC                           586 (88.79)                       628 (88.45)                       0.799       0.957 (0.684--1.339)
                                     CG+GG                        74 (11.21)                        82 (11.55)                        Reference   
                 Recessive model     GG                           3 (0.45)                          3 (0.42)                          0.874       0.878 (0.176--4.393)
                                     CG+CC                        657 (99.55)                       707 (99.58)                       Reference   
  rs35138901     Genotypes           CC                           4 (0.61)                          2 (0.28)                          0.469       0.532 (0.097--2.933)
                                     CT                           93 (14.09)                        115 (16.20)                       0.252       1.191 (0.883--1.606)
                                     TT                           563 (85.30)                       593 (83.52)                       Reference   
                 Alleles             C                            101 (7.65)                        119 (8.38)                        0.483       1.104 (0.837--1.445)
                                     T                            1,219 (92.35)                     1,301 (91.62)                     Reference   
                 Dominant model      TT                           563 (85.30)                       593 (83.52)                       0.312       0.859 (0.639--1.154)
                                     CT+CC                        97 (14.70)                        117 (16.48)                       Reference   
                 Recessive model     CC                           4 (0.61)                          2 (0.28)                          0.450       0.518 (0.094--2.852)
                                     CT+TT                        656 (99.39)                       708 (99.72)                       Reference   
  ***ZFAS1***                                                                                                                                     
  rs237742       Genotypes           TT                           91 (13.79)                        104 (14.65)                       0.994       0.999 (0.717--1.391)
                                     CT                           322 (48.79)                       320 (45.07)                       0.212       0.863 (0.685--1.088)
                                     CC                           247 (37.42)                       286 (40.28)                       Reference   
                 Alleles             T                            504 (38.18)                       528 (37.18)                       0.590       0.958 (0.821--1.119)
                                     C                            816 (61.82)                       892 (62.82)                       Reference   
                 Dominant model      CC                           247 (37.42)                       286 (40.28)                       0.309       1.121 (0.900--1.395)
                                     CT+TT                        413 (62.58)                       424 (59.72)                       Reference   
                 Recessive model     TT                           91 (13.79)                        104 (14.65)                       0.611       1.083 (0.797--1.470)
                                     CT+CC                        569 (86.21)                       606 (85.35)                       Reference   
  rs73116127     Genotypes           AA                           1 (0.15)                          3 (0.42)                          0.384       2.739 (0.283--26.506)
                                     GA                           109 (16.52)                       133 (18.73)                       0.294       1.162 (0.878--1.538)
                                     GG                           550 (83.33)                       574 (80.85)                       Reference   
                 Alleles             A                            111 (8.41)                        139 (9.79)                        0.211       1.182 (0.910--1.535)
                                     G                            1,209 (91.59)                     1,281 (90.21)                     Reference   
                 Dominant model      GG                           550 (83.33)                       574 (80.85)                       0.253       0.850 (0.643--1.123)
                                     AA+GA                        110 (16.67)                       136 (19.15)                       Reference   
                 Recessive model     AA                           1 (0.15)                          3 (0.42)                          0.398       2.661 (0.275--25.738)
                                     GG+GA                        659 (99.85)                       707 (99.58)                       Reference   
  rs6125607      Genotypes           TT                           74 (11.21)                        48 (6.76)                         0.007       0.576 (0.387--0.857)
                                     CT                           277 (41.97)                       310 (43.66)                       0.978       1.003 (0.801--1.256)
                                     CC                           309 (46.82)                       352 (49.58)                       Reference   
                 Alleles             T                            425 (32.20)                       406 (28.59)                       0.040       0.843 (0.716--0.992)
                                     C                            895 (67.80)                       1,014 (71.41)                     Reference   
                 Dominant model      CC                           309 (46.82)                       352 (49.58)                       0.407       1.095 (0.884--1.356)
                                     TT+CT                        351 (53.18)                       358 (50.42)                       Reference   
                 Recessive model     TT                           74 (11.21)                        48 (6.76)                         0.005       0.576 (0.393--0.844)
                                     CC+TC                        586 (88.78)                       662 (93.23)                       Reference   
  rs6125608      Genotypes           GG                           9 (1.36)                          11 (1.55)                         0.716       1.181 (0.483--2.890)
                                     GA                           125 (18.94)                       158 (22.25)                       0.153       1.213 (0.931--1.582)
                                     AA                           526 (79.70)                       541 (76.20)                       Reference   
                 Alleles             G                            143 (10.83)                       180 (12.68)                       0.135       1.195 (0.946--1.509)
                                     A                            1,177 (89.17)                     1,240 (87.32)                     Reference   
                 Dominant model      AA                           526 (79.70)                       541 (76.20)                       0.147       0.826 (0.638--1.069)
                                     GG+GA                        134 (20.30)                       169 (23.80)                       Reference   
                 Recessive model     GG                           9 (1.36)                          11 (1.55)                         0.780       1.136 (0.465--2.775)
                                     AA+GA                        651 (98.64)                       699 (98.45)                       Reference   

*After FDR correction, no P value was statistically significant (all P \> 0.05)*.

In *ANRIL* gene, the rs1412830 TT genotype frequency was significantly increased in RA patients in comparison to normal controls, while the rs944796 GG genotype frequency was significantly decreased (TT vs. CC: *P* = 0.017; GG vs. CC: *P* = 0.013, respectively). In addition, an increased risk of rs1412830 variant, as well as a decreased risk of rs944796, was observed under the recessive model (TT vs. CC+CT: *P* = 0.016; GG vs. CC+GC: *P* = 0.008, respectively). However, these significant associations were disappeared after multiple testing by FDR correction (all *P* \> 0.05). Comparing the genotype and allele frequencies of the ZFAS1 rs6125607 polymorphism among RA patients and normal controls, we found that TT genotype and T allele frequencies were significantly higher in RA patients than normal controls (TT vs. CC: *P* = 0.007; T vs. C: *P* = 0.040, respectively), and an increased risk of rs6125607 polymorphism existed in recessive model (TT vs. CC+TC: *P* = 0.005). After FDR correction, these differences were not statistically significant (TT vs. CC: *P* = 0.181; T vs. C: *P* = 0.496, TT vs. CC+TC: *P* = 0.080, respectively). Similarly, no significant associations between *lnc-DC, MALAT1* genes polymorphism and RA susceptibility were found ([Table 1](#T1){ref-type="table"}).

To examine the potential genetic association between the genotype, allele frequencies of *ANRIL, lnc-DC, MALAT1, ZFAS1* genes and anti-CCP, RF in RA patients, we performed a case-only analysis ([Table S1](#SM1){ref-type="supplementary-material"}). In *ANRIL* gene, the rs944796 G allele, rs2518723 T allele frequencies were significantly increased in RA patients with anti-CCP-positive when compared to patients with anti-CCP-negative (all *P* \< 0.05), while rs3217992 T allele frequency was reduced (*P* = 0.039) ([Table 2](#T2){ref-type="table"}). No significant differences existed in allele and genotype frequencies of *lnc-DC, MALAT1, ZFAS1* genes.

###### 

The positive findings of associations between *ANRIL* gene polymorphisms and anti-CCP of RA patients.

  **SNP**     **Allele**   **Clinical features**   **Group**   **Alleles** ***n*** **(%)**   ***P* value**   
  ----------- ------------ ----------------------- ----------- ----------------------------- --------------- -----------
  rs944796    C/G          Anti-CCP                Positive    853 (79.28)                   223 (20.72)     **0.039**
                                                   Negative    143 (86.14)                   23 (13.86)      
  rs2518723   C/T          Anti-CCP                Positive    615 (57.16)                   461 (42.84)     **0.039**
                                                   Negative    109 (65.66)                   57 (34.34)      
  rs3217992   C/T          Anti-CCP                Positive    553 (51.39)                   523 (48.61)     **0.039**
                                                   Negative    71 (42.77)                    95 (57.23)      

*Bold value means P \< 0.05*.

Haplotype Analysis
------------------

Six main haplotypes (CCATC, CCTCC, CCTCT, CCTTC, CGTTC, TCATC) for *ANRIL*, three main haplotypes (AG, GA, GG) for lnc-DC, six main haplotypes (ACTCT, AGCCT, AGTCC, AGTCT, GGTCT, GGTGT) for *MALAT1* and five main haplotypes (CACA, CGCA, CGCG, CGTA, TGCA) for *ZFAS1* were detected by SHEsis software ([Table 3](#T3){ref-type="table"}). The results demonstrated that the haplotype CGTA frequency was significantly higher in RA patients than normal controls (*OR* = 1.191, 95% CI: 1.012--1.402, *P* = 0.036).

###### 

Haplotype analysis of lncRNA genes in RA patients and controls.

  **Haplotype**                                                            **RA patients \[*n*(%)\]**   **Controls \[*n*(%)\]**   ***P* value**   ***OR* (95% CI)**
  ------------------------------------------------------------------------ ---------------------------- ------------------------- --------------- ----------------------
  ***ANRIL*** **rs1412830- rs944796- rs61271866- rs2518723- rs3217992**                                                                           
  CCATC                                                                    91.88 (7.0)                  125.21 (8.8)              0.077           0.776 (0.586--1.028)
  CCTCC                                                                    105.84 (8.0)                 108.60 (7.6)              0.692           1.058 (0.800--1.400)
  CCTCT                                                                    614.30 (46.5)                621.58 (43.8)             0.109           1.135 (0.972--1.324)
  CCTTC                                                                    116.57 (8.8)                 128.95 (9.1)              0.847           0.974 (0.749--1.268)
  CGTTC                                                                    190.02 (14.4)                220.98 (15.6)             0.419           0.916 (0.742--1.132)
  TCATC                                                                    122.50 (9.3)                 135.90 (9.6)              0.824           0.971 (0.751--1.256)
  ***Lnc-DC*** **rs7217280- rs10515177**                                                                                                          
  AG                                                                       58.00 (4.4)                  85.00 (6.0)               0.061           0.722 (0.512--1.017)
  GA                                                                       1,218.00 (92.3)              1,293.00 (91.1)           0.250           1.173 (0.893--1.540)
  GG                                                                       44.00 (3.3)                  42.00 (3.0)               0.573           1.131 (0.736--1.738)
  ***MALAT1*** **rs619586- rs4102217- rs591291- rs11227209- rs35138901**                                                                          
  ACTCT                                                                    192.89 (14.6)                227.78 (16.0)             0.297           0.895 (0.727--1.103)
  AGCCT                                                                    769.36 (58.3)                804.34 (56.6)             0.393           1.069 (0.918--1.244)
  AGTCC                                                                    96.61 (7.3)                  115.61 (8.1)              0.419           0.890 (0.672--1.180)
  AGTCT                                                                    133.58 (10.1)                147.87 (10.4)             0.796           0.968 (0.756--1.239)
  GGTCT                                                                    45.92 (3.5)                  32.65 (2.3)               0.065           1.531 (0.971--2.413)
  GGTGT                                                                    75.01 (5.7)                  83.88 (5.9)               0.799           0.959 (0.696--1.322)
  ***ZFAS1*** **rs237742- rs73116127- rs6125607- rs6125608**                                                                                      
  CACA                                                                     111.00 (8.4)                 136.66 (9.6)              0.259           0.860 (0.661--1.118)
  CGCA                                                                     137.00 (10.4)                170.49 (12.0)             0.170           0.846 (0.667--1.074)
  CGCG                                                                     143.00 (10.8)                177.70 (12.5)             0.164           0.847 (0.670--1.070)
  CGTA                                                                     425.00 (32.2)                403.76 (28.4)             **0.036**       1.191 (1.012--1.402)
  TGCA                                                                     504.00 (38.2)                527.90 (37.2)             0.622           1.040 (0.891--1.214)

*Frequency \< 0.03 in both controls and RA patients has been dropped. Bold value means P \< 0.05*.

LncRNAs Expression Levels in PBMCs From RA Patients and Normal Controls
-----------------------------------------------------------------------

We further analyzed the association of ANRIL, lnc-DC, MALAT1, ZFAS1 levels with RA patients by qRT-PCR. As shown in [Table 4](#T4){ref-type="table"}, the expression levels of ANRIL, lnc-DC, MALAT1, ZFAS1 in PBMCs were significantly reduced in RA patients than normal controls (all *P* \< 0.001). However, the differences in these lncRNAs levels between anti-CCP-positive RA patients and anti-CCP-negative RA patients, as well as RA patients with RF-positive and RF-negative RA patients, were not statistically significant.

###### 

Comparison of lncRNAs expression level in PBMCs between different subgroups.

  **Group**                            **Number**   **ANRIL**              ***P* value**   **Lnc-DC**             ***P* value**   **MALAT1**             ***P* value**   **ZFAS1**              ***P* value**
  ------------------------------------ ------------ ---------------------- --------------- ---------------------- --------------- ---------------------- --------------- ---------------------- ---------------
  RA patients                          120          0.605 (0.382, 0.849)   \<0.001         0.378 (0.269, 0.586)   \<0.001         0.409 (0.257, 0.533)   \<0.001         0.458 (0.352, 0.646)   \<0.001
  Normal controls                      120          0.853 (0.612, 1.147)                   0.818 (0.537, 1.166)                   0.932 (0.627, 1.228)                   0.870 (0.625, 1.161)   
  RA patients with anti-CCP-positive   99           0.603 (0.404, 0.868)   0.866           0.387 (0.264, 0.591)   0.920           0.418 (0.250, 0.543)   0.681           0.469 (0.362, 0.635)   0.926
  RA patients with anti-CCP-negative   21           0.619 (0.350, 0.823)                   0.358 (0.284, 0.577)                   0.372 (0.270, 0.489)                   0.391 (0.337, 0.676)   
  RA patients with anti-RF-positive    101          0.629 (0.404, 0.870)   0.210           0.344 (0.268, 0.561)   0.453           0.415 (0.251, 0.575)   0.563           0.469 (0.352, 0.642)   0.997
  RA patients with anti-RF-negative    19           0.510 (0.360, 0.675)                   0.436 (0.273, 0.614)                   0.379 (0.306, 0.474)                   0.444 (0.349, 0.682)   

The correlation of ANRIL, lnc-DC, MALAT1, ZFAS1 expression levels with clinical parameters, disease activity of RA patients were also analyzed, and the results shown that the expression level of ZFAS1 was negatively associated with CRP in RA patients (*P* = 0.002). However, there were no significant correlations of these lncRNAs levels with DAS28 of RA patients ([Table 5](#T5){ref-type="table"}). The potential influence of main medical therapies including glucocorticoids, disease-modifying antirheumatic drugs (DMARDs), biologics on lncRNAs expression levels in RA patients were assessed in this study. Similarly, no significant association was found ([Table 6](#T6){ref-type="table"}).

###### 

Association of lncRNAs expression levels with clinical parameters, disease activity of RA patients.

  **Parameters**   **Number**   **ANRIL**   **Lnc-DC**   **MALAT1**   **ZFAS1**                             
  ---------------- ------------ ----------- ------------ ------------ ----------- -------- ------- -------- -------
  C3               107          −0.035      0.719        −0.054       0.583       0.077    0.431   −0.100   0.305
  C4               106          −0.122      0.213        −0.027       0.781       0.094    0.339   −0.020   0.840
  ESR              118          0.035       0.705        0.034        0.712       0.069    0.457   −0.090   0.334
  CRP              118          −0.038      0.682        −0.094       0.313       −0.178   0.054   −0.278   0.002
  DAS28            118          0.071       0.444        0.139        0.132       −0.078   0.399   −0.036   0.695

###### 

Association of these lncRNAs expression levels with medical therapy of RA patients.

  **Group**         **Number**   **ANRIL level**        ***P* value**   **Lnc-DC level**       ***P* value**   **MALAT1 level**       ***P* value**   **ZFASA level**        ***P* value**
  ----------------- ------------ ---------------------- --------------- ---------------------- --------------- ---------------------- --------------- ---------------------- ---------------
  Glucocorticoids                                       0.302                                  0.764                                  0.340                                  0.500
     NA             30           0.516 (0.344, 0.948)                   0.445 (0.256, 0.608)                   0.450 (0.259, 0.581)                   0.452 (0.355, 0.597)   
     ≤7.5 mg/d      28           0.573 (0.323, 0.831)                   0.325 (0.250, 0.512)                   0.437 (0.240, 0.561)                   0.464 (0.299, 0.614)   
     \>7.5 mg/d     62           0.634 (0.451, 0.834)                   0.348 (0.278, 0.580)                   0.389 (0.374, 0.703)                   0.462 (0.374, 0.703)   
  DMARDs                                                0.532                                  0.232                                  0.366                                  0.257
     No             39           0.619 (0.428, 0.901)                   0.414 (0.269, 0.614)                   0.404 (0.226, 0.539)                   0.410 (0.349, 0.575)   
     Yes            81           0.587 (0.350, 0.835)                   0.338 (0.265, 0.540)                   0.418 (0.273, 0.533)                   0.471 (0.361, 0.679)   
  Biologics                                             0.489                                  0.423                                  0.211                                  0.095
     No             111          0.603 (0.399, 0.838)                   0.377 (0.266, 0.570)                   0.408 (0.256, 0.533)                   0.455 (0.345, 0.618)   
     Yes            9            0.760 (0.291, 1.120)                   0.461 (0.289, 0.687)                   0.432 (0.395, 0.588)                   0.632 (0.392, 0.902)   

Associations Between lncRNAs Genes Polymorphisms With Their Levels in RA Patients
---------------------------------------------------------------------------------

To examine the associations between the respective genotype frequencies of these lncRNAs genes with their expression levels in RA patients, we included 65 patients for analysis. However, there were no significant differences regarding these lncRNAs expression levels between their disparate genotypes of RA patients ([Table 7](#T7){ref-type="table"}).

###### 

Association between lncRNA levels with their respective genotype in RA patients.

  ***ANRIL* SNPs**        **Genotype**   **Number**   ***ANRIL* level**       ***P* value**
  ----------------------- -------------- ------------ ----------------------- -------------------
  rs1412830               CC             49           0.542 (0.404, 0.742)    0.210
                          CT             14           0.418 (0.267, 0.672)    
                          TT             2            0.913 (0.504, 1.322)    
  rs944796                CC             36           0.585 (0.371, 0.798)    0.437
                          GC             27           0.493 (0.360, 0.786)    
                          GG             2            0.325 (0.088, 0.562)    
  rs61271866              TT             44           0.562 (0.404, 0.764)    0.251
                          TA             19           0.497 (0.274, 0.641)    
                          AA             2            0.913 (0.504, 1.323)    
  rs2518723               CC             21           0.603 (0.414, 0.975)    0.329
                          CT             28           0.520 (0.339, 0.646)    
                          TT             16           0.476 (0.335, 0.818)    
  rs3217992               CC             21           0.459 (0.296, 0.647)    0.219
                          CT             29           0.582 (0.472, 0.839)    
                          TT             15           0.587 (0.404, 0.955)    
  ***Lnc-DC*** **SNPs**   **Genotype**   **Number**   **Lnc-DC level**        ***P*** **value**
  rs7217280               GG             63           0.378 (0.282, 0.603)    0.649
                          GA             2            0.458 (0.431, 0.484)    
                          AA             0                                    
  rs10515177              GG             58           0.383 (0.289, 0.600)    0.703
                          GA             7            0.431 (0.269, 0.629)    
                          AA             0                                    
  ***MALAT1*** **SNPs**   **Genotype**   **Number**   **MALAT1 level**        ***P*** **value**
  rs619586                AA             55           0.415 (0.253, 0.530)    0.167
                          GA             10           0.285 (0.128, 0.473)    
                          GG             0                                    
  rs4102217               GG             48           0.337 (0.214, 0.486)    0.064
                          CG             13           0.477 (0.381, 0.634)    
                          CC             4            0.463 (0.380, 0.851)    
  rs591291                CC             24           0.416 (0.257, 0.502)    0.905
                          CT             29           0.415 (0.199, 0.508)    
                          TT             12           0.389 (0.155, 0.617)    
  rs11227209              CC             59           0.415 (0.245, 0.530)    0.267
                          CG             6            0.285 (0.181, 0.473)    
                          GG             0                                    
  rs35138901              TT             56           0.418 (0.257, 0.526)    0.068
                          CT             9            0.193 (0.161, 0.454)    
                          CC             0                                    
  ***ZFAS1*** **SNPs**    **Genotype**   **Number**   **ZFAS1 level**         ***P*** **value**
  rs237742                CC             31           0.471 (0.376, 0.584)    0.392
                          CT             30           0.394 (0.300, 0.605)    
                          TT             4            0.423 (0.359, 0.783)    
  rs73116127              GG             51           0.444 (0.362, 0.6001)   0.342
                          GA             14           0.377 (0.325, 0.529)    
                          AA             0                                    
  rs6125607               CC             25           0.398 (0.351, 0.516)    0.375
                          CT             31           0.434 (0.316, 0.618)    
                          TT             9            0.523 (0.419, 0.655)    
  rs6125608               AA             50           0.438 (0.353, 0.600)    0.998
                          GA             14           0.428 (0.344, 0.652)    
                          CC             1            0.444                   

*Median (interquartile range)*.

Discussion {#s4}
==========

To date, the exact pathogenic mechanism of RA remains largely unknown, although several pro-inflammatory cytokines including tumor necrosis factor-α (TNF-α), IL-6, IL-1b have been reported to related to the occurrence of RA ([@B25]--[@B27]). Previous studies have shown that lncRNAs had distinct and specific roles in the activation and differentiation modulating of immune cell, and lncRNAs played an important role in autoimmune diseases ([@B28]). A study detected lncRNA transcription in CD14+ monocytes isolated from peripheral blood cells of RA patients before and after anti-IL-6R (tocilizumab) or anti-TNF-α (adalimumab) therapy by a microarray-based experiment. They observed that 7,419 lncRNAs expression levels were altered by either IL-6 or TNF-α, 85 of which exhibited were significant changed ([@B29]). These results suggested that lncRNAs were very important in the molecular pathophysiology of RA. In the present study, our results demonstrated that lower expression levels of ANRIL, lnc-DC, MALAT1, ZFAS1 existed in RA patients, and *ANRIL, lnc-DC, MALAT1, ZFAS1* genes were not related to RA susceptibility.

*ANRIL* gene was located in the chromosome 9p21 region, and it was the well-defined genetic risk locus related to several diseases such as coronary artery disease (CAD), diabetes, and breast cancer ([@B30]--[@B32]). Our results implied that *ANRIL* rs1412830, rs944796 variant might associated with RA susceptibility, while the significant associations were disappeared after multiple testing. However, we found that *ANRIL* rs944796 G, rs2518723 T, rs3217992 T allele frequencies were significantly associated with anti-CCP in RA patients, this suggested to us that *ANRIL* gene variation might be involved in the RA development. In addition, disease-associated SNPs resided in this region had been reported to change the expression of ANRIL, demonstrating that altered ANRIL expression might be involved in predisposition to these disorders ([@B33]). Two SNPs (rs10757278 and rs1333045) in *ANRIL*, which had been highlighted as potential causal variants for the association with CAD, were reported to be associated with abnormal ANRIL expression level in Peripheral blood ([@B34], [@B35]). Moreover, our results demonstrated that compared with normal controls, ANRIL expression level was significantly decreased in PBMC from RA patients. We further explored the influence of the five SNPs on ANRIL level in PBMC from RA patients, unfortunately, there were no significant differences regarding ANRIL level between disparate genotypes of these SNPs.

In a previous study, the authors discovered a new lncRNA (named lnc-DC) located on chromosome 17 region, which near signal transducer and activator of transcription 3 (*STAT3*) gene ([@B36]). There were increasing researches to explore the contribution of lnc-DC in autoimmune diseases. Shaker et al. found that serum level of lnc-DC in multiple sclerosis (MS) patients were significantly increased, and serum lnc-DC level maybe used to as a potential novel biomarkers for MS diagnosis ([@B37]). One of our recent studies shown that the lnc-DC expression level was significantly decreased in PBMCs from SLE patients than controls, while *lnc-DC* rs10515177 variant was not associated with SLE susceptibility ([@B38]). Similarly, the lnc-DC expression level was significantly lower in PBMC from RA patients than normal controls in the present study. We also explore the potential association of two SNP (rs7217280, rs10515177) in *lnc-DC* with RA susceptibility, however, no significant relationship was found. Our study provided the first evidence that lnc-DC might be involved in the development of RA, and the specific roles of *lnc-DC* genetic variation in pathophysiology of RA need to be further explored.

MALAT1 was expressed on chromosome 11q13, and widely expressed in multiple normal tissues such as reproductive, endocrine and immune systems with an important role in autoimmune diseases including RA, SLE, MS ([@B18], [@B19], [@B37], [@B39]). Quercetin is a dietary antioxidant, which has been shown to be effective in the treatment of arthritis in pre-clinical studies, and Pan et al. tried to analyze the mechanisms responsible for the quercetin-induced FLS apoptosis in RA patients ([@B19]). Their data indicated that quercetin induced FLS apoptosis in RA patients via upregulating MALAT1, and MALAT1 promoted apoptosis by inhibiting the activation of the phosphoinositide 3-kinase (PI3K)/AKT pathway. In this study, decreased MALAT1 expression level in PBMC from RA patients was firstly reported, while *MALAT1* genetic variation was not correlated with RA risk. Our findings provided new evidence that MALAT1 might be involved in RA development.

ZFAS1, located at chromosomal band 20q13.13, was reported as an important player to regulate the development of human cancers including glioma, lung, ovary, gastric, and breast cancer ([@B40]--[@B42]). In addition, ZFAS1 was found to promote chondrocytes proliferation, migration, and inhibit apoptosis and matrix synthesis in osteoarthritis (OA), and ZFAS1 expression level was downregulated in OA chondrocytes in comparison to mild chondrocytes ([@B43]). Another study by Xiao et al. also found more than five times ZFAS1 level in the healthy appearing area of cartilage compared with the pathology area in human knee osteoarthritis ([@B44]). Similarly, our results demonstrated that the expression of ZFAS1 in PBMCs was significantly reduced in RA patients than normal controls, and associated with CRP in RA. In the present study, we also analyzed the potential relationship between rs237742, rs73116127, rs6125607, rs6125608 variants in *ZFAS1* and genetic susceptibility to RA, and no difference achieved statistical significance. However, haplotype analysis implied that the haplotype CGTA frequency for *ZFAS1* was significantly higher in RA patients than normal controls. These founding would help improve our understanding of the roles of *ZFAS1* genetic variants in the pathogenesis of RA.

In conclusion, our study provided the first evidence that *ANRIL, lnc-DC, MALAT1, ZFAS1* genes polymorphisms might not be associated with RA susceptibility in the Chinese population. However, several SNPs in *ANRIL* were related to anti-CCP in RA. In addition, alternations of ANRIL, lnc-DC, MALAT1, ZFAS1 levels and significant correlations of ZFAS1 level with CRP in RA patient demonstrated that these lncRNAs might be regarded as an auxiliary biomarker for RA diagnosis, as well as used to distinguish RA serotypes.

However, some limitations existed in our study should be acknowledged. Firstly, this study does not eliminate the potential influence of ethnic background, environmental factor. Secondly, we are not able to assess the associations between these lncRNAs levels and disease severity, clinical variables, and therapeutic schedule of RA patients over a long period in this case-control study. Finally, our sample size may not be sufficient, and lead to the low power of this study. Hence, replication studies with larger sample size, different ethnic populations are awaited to further explore the exact role of these lncRNAs in RA.
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